Contract research and manufacturing organization Syngene International (NSE: SYNGENE) expects second-half revenue to improve on the strength of its existing order book and customer delivery commitments, even as it maintains its full-year guidance for a single-digit top-line decline.
The Bottom Line
- Revenue Trajectory: Q2FY27 revenue rose 13% sequentially to ₹833 crore, though it dropped 9% year-on-year from ₹911 crore.
- Margin Recovery: Operating EBITDA margin bounced back to 18% from 12% in Q1FY27, though it remains below the 22% reported a year prior.
- Growth Drivers: Management points to upcoming animal health manufacturing supplies and long-term biologics capacity as primary catalysts.
Q2FY27 Earnings and the Zoetis Supply Factor
The company reported a profit after exceptional items of ₹32 crore for the quarter ending September, recovering from a loss of ₹9 crore in the June quarter. Managing Director and Chief Executive Officer Siddharth Mittal stated that the second half of the fiscal year will outperform the first, pointing to visibility from the current order book and scheduled fourth-quarter supplies to animal health firm Zoetis (NYSE: ZTS).
The year-on-year revenue contraction directly stems from the absence of manufacturing revenue for Librella, an animal-health drug developed for Zoetis. Librella contributed significantly to the same period last year but brought in nothing during the recent quarter. Mittal noted that following the fourth-quarter production run, manufacturing runs for the product will pause for an extended period, creating temporary idle capacity in the biologics unit. The firm intends to backfill this capacity with multiple clients rather than relying on a single large account.
| Financial Metric | Q2FY27 | Q1FY27 | Q2FY26 (YoY) |
|---|---|---|---|
| Net Profit After Exceptions (₹ crore) | 32 | -9 | Not Disclosed |
| Operating EBITDA Margin (%) | 18% | 12% | 22% |
Hedge Losses and Operational Margins
Operating EBITDA margin reached 18% in the September quarter, marking a recovery from 12% in the preceding period. However, margins remain compressed compared to the 22% reported a year earlier. Mittal attributed the year-on-year pressure primarily to hedge losses tied to large dedicated center contracts.
Biologics Expansion and US Capacity Strategy
Syngene International maintains 50,000 litres of bioreactor capacity split across two Indian facilities and one in the United States. Management views biologics manufacturing as the primary long-term growth engine, though commercial revenue from the current pipeline is not expected to materialize until after fiscal year 2027.
The company aims to capitalize on global supply chain shifts as international clients diversify manufacturing away from China, supported by legislative measures like the US BioSecure Act. Its initial manufacturing agreement for the Bayview facility in the United States involves early-stage development work in Bengaluru, followed by technology transfer and scale-up for regulatory filings. The site is scheduled to produce three to four filing batches through fiscal year 2028, though meaningful commercial revenue requires successful regulatory approvals and subsequent product rollouts.
Capital Allocation and Workforce Adjustments
Capital expenditure reached ₹200 crore through the first half of fiscal year 2027, with spending projected to accelerate in the second half as the first phase of the Bayview facility commissions during the current quarter. Additional capital is allocated toward laboratory automation, facility upgrades, and AI-led capabilities.
On the operational side, manpower rationalization is nearing completion, with financial savings anticipated to reflect in results starting in the third quarter. The restructuring involved right-sizing teams, particularly within the discovery business segment, following earlier client losses.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
